SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced revenue guidance for FY2027, and announced that it has received a $5 million payment from Eli Lilly. In association with its former inflammatory bowel disease drug program developed previously and sold outright to Eli Lilly, VivoSim has received $5 million as a m

Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD7-targeted mRNA/LNP delivery approach Lead candidate TPST-4003 combines proprietary CD7-targeted mRNA/LNP delivery with a clinically validated dual-targeting CD19/BCMA CAR construct to support broad B-cell lineage reset across multiple indications First investigator-initiated trial expected to enroll approximately 10 patients with nervous system autoimmune diseases, including MG

Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and commercialization capabilities to explore a next-generation drug innovation model CAMBRIDGE, Mass. and TAIPEI, July 14, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a multi-target strategic alliance with Bora Pharmaceuticals Co., Ltd. ("Bora"; TWSE: 6472; OTCQX: BORAY), a gl

HANGZHOU, China and SHANGHAI and BOSTON, July 14, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that patient enrollment was completed on July 9 in the Phase III clinical trial evaluating its core product zemprocitinib capsules for the treatment of active ankylosing spondylitis (AS). The successful completion of enrollment marks an important milestone i

ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients with Stage IV Renal Cell Carcinoma (RCC) with High CD70 Expression Single Dose of ALLO-316 Produced Durable Responses in this Cohort with All Responders Progression-Free at the Time of Analysis Responses Range from 8 to 18+ Months, with Median Overall Survival Not Yet Reached Safety Pro Manageable with Proactive Diagnostic and Management Strategies Effective in Mitigating IEC-HS ALLO-316 Demonstrate

Strong U.S. demand and new product launches drive first-half sales in Human Pharma Net sales reach EUR 15.8 billion, led by JARDIANCE® and successful U.S. launches Positive Phase III data for survodutide and pipeline progress strengthen long-term outlook Boehringer Ingelheim reported continued sales growth in the first half of 2026, driven by strong growth in the U.S. due to increased demand for JARDIANCE® (empagliflozin) and successful new launches. Group net sales increased by 16.2%* to EUR 15

Pittsburgh, Pennsylvania and Toronto, Ontario--(News - July 15, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) (" Sharp " or the " Company ") is pleased to announce that it is arranging a non-brokered private placement to raise gross proceeds of up to C$1,365,000 (the " Offering "). The Offering will consist of common shares in the capital of the Company (the " Common Shares ") priced at not less than C$0.91 per Common Share. The Company expects the Offering to close in Q3 2026. Th

New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts Builds on compre

iStock/ Rasi Bhadramani After a sluggish 2025, biotech IPOs have roared back to life. Fueled by resilient stock performances and improving market sentiment, the total number of public debuts so far this year has already eclipsed 2025’s total. Biopharma’s exit activity in the first half of 2026 was one for the books. Eighteen industry IPOs occurred in the first half of this year, and two of these set records as the largest public debuts in biotech history . That number far exceeds last year’s to

SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to t